Adherence rates lower than 95% are associated with virologic failure
1 October 2001. Related: Antiretrovirals.
Antiretrovirals
Discontinuation rates similar between HAART regimens
1 October 2001. Related: Antiretrovirals.
African patients with non-B subtypes respond to HAART
1 October 2001. Related: Antiretrovirals.
Entry inhibitor updates from the 1st IAS
1 September 2001. Related: Conference reports, Antiretrovirals.
Durable HIV treatment benefit despite low-level viraemia: reassessing definitions of success or failure
1 September 2001. Related: Antiretrovirals.
Anticancer drug 9-nitrocamptothecin (9NC) inhibits HIV-1 replication
1 September 2001. Related: Antiretrovirals.
T-20: will long-term use weaken the immune system’s ability to fight HIV?
30 July 2001. Related: Antiretrovirals.
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons
30 July 2001. Related: Antiretrovirals.
Ritonavir approved in Europe as pharmacokinetic enhancer for use with other antiretrovirals
30 July 2001. Related: Antiretrovirals.
Tenofovir: Gilead applies for approval, expanded access relaxed
30 June 2001. Related: Antiretrovirals.
Outcome of patients with discordant responses to HAART
17 May 2001. Related: Antiretrovirals, Treatment strategies.
Self-reported symptoms after starting HAART help predict adherence
17 May 2001. Related: Antiretrovirals, Side effects.
DuPont applies to FDA for approval of one-tablet, once daily formulation of efavirenz
17 May 2001. Related: Antiretrovirals.
Patient age influences CD4+ cell recovery with HAART
17 May 2001. Related: Antiretrovirals.
First randomised trial shows clinical benefit of TDM for people using nelfinavir or indinavir containing combinations
17 May 2001. Related: Conference reports, Antiretrovirals.
Preliminary data from four studies of double PI regimen using once daily Fortovase plus “mini dose” ritonavir
17 May 2001. Related: Antiretrovirals, Treatment strategies.
Roche and Trimeris announce US sites and investigators for T-20 phase III study; activists want wider access to drug for sickest AIDS patients
17 April 2001. Related: Antiretrovirals, Treatment access.
European marketing approval granted for lopinavir/r (Kaletra)
17 April 2001. Related: Antiretrovirals.
HIV-1 strains using the CXCR4 co-receptor are suppressed with potent therapy
17 April 2001. Related: Antiretrovirals.
Efavirenz use in HIV-positive children
17 April 2001. Related: Antiretrovirals, Paediatric care.
Drugs need not be stopped because of neutropenia in HIV-positive patients
17 March 2001. Related: Antiretrovirals, Side effects.
Capravirine clinical trials restricted: additional safety evaluation required
17 March 2001. Related: Antiretrovirals.
Gilead announces start of early access program for investigational anti-HIV agent tenofovir DF in United States and France
17 March 2001. Related: Antiretrovirals.
Differentiating within and between drug classes: sometimes it’s toxicity, sometimes its efficacy
17 March 2001. Related: Conference reports, Antiretrovirals.
HAART initiated during primary HIV infection leads to faster and more complete immune reconstitution
17 January 2001. Related: Antiretrovirals.
Viral response to antiretroviral therapy slower during acute HIV-1 infection
17 January 2001. Related: Antiretrovirals.
European Commission approves GlaxoSmithKline’s HIV triple therapy Trizivir
17 January 2001. Related: Antiretrovirals.
Lamivudine withdrawal may reactivate HBV in HIV-positive patients
17 January 2001. Related: Antiretrovirals, Hepatitis coinfection.
CPMP delivers positive opinion on Kaletra
17 January 2001. Related: Antiretrovirals.
Clinical issues arising from a single treatment interruption
17 December 2000. Related: Conference reports, Antiretrovirals.
A review of new anti-HIV drugs in development
17 December 2000. Related: Conference reports, Antiretrovirals.
Adherence and HAART: unique approaches to evaluating and improving adherence discussed
17 December 2000. Related: Conference reports, Antiretrovirals.
Importance of intensive adherence support for people with HIV-related neurological symptoms
17 December 2000. Related: Antiretrovirals.
Efavirenz side effects become long-term for over one in three
17 December 2000. Related: Antiretrovirals, Side effects.
ABT-378/r oral formulation available in UK
17 December 2000. Related: Antiretrovirals.
Trimeris, Roche to begin phase III pivotal trials of T-20 HIV fusion inhibitor
17 December 2000. Related: Antiretrovirals.
United States FDA approves Kaletra for HIV infection
17 October 2000. Related: Antiretrovirals.
Videx EC (ddI, didanosine) – food restrictions
16 September 2000. Related: Antiretrovirals.
Importance of protease inhibitor plasma levels in patients treated with genotypic-guided therapy
16 September 2000. Related: Antiretrovirals.
Flavopiridol inhibits cellular processes essential to replication of HIV
16 September 2000. Related: Antiretrovirals.
Abbott expands early-access program for ABT-378/r (Kaletra)
16 September 2000. Related: Antiretrovirals.
Roche and Trimeris announce intention to manufacture commercial supplies of anti-HIV fusion inhibitor T-20
16 September 2000. Related: Antiretrovirals.
PRO-542 shows efficacy in trial
16 September 2000. Related: Antiretrovirals.
New potential dual NNRTI-based combinations
16 August 2000. Related: Conference reports, Antiretrovirals.
Once-daily protease-based regimens
16 August 2000. Related: Conference reports, Antiretrovirals, Treatment strategies.
European drug approvals: amprenavir, ddI EC, Trizivr and Kaletra
16 August 2000. Related: Antiretrovirals.
DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing
16 July 2000. Related: Conference reports, Antiretrovirals.
Indinavir/ritonavir at 400/400 mg or 800/100 mg as intensification
16 July 2000. Related: Conference reports, Antiretrovirals.
Ritonavir/saquinavir combination: effect of ritonavir dosage
16 July 2000. Related: Conference reports, Antiretrovirals.
Nevirapine vs efavirenz: the SENC trial
16 July 2000. Related: Conference reports, Antiretrovirals.
Nevirapine daily exposure for daily 400 mg dose compared to 200 mg twice-daily
16 July 2000. Related: Antiretrovirals.
Didanosine systemic exposure in children similar with or without food, high interpatient variability suggests TDM to titrate individual dosages
15 June 2000. Related: Antiretrovirals, Paediatric care.
Low level HIV replication despite good virological response may explain CD4+ cell decline in a patient receiving combination nucleoside analogue therapy
15 June 2000. Related: Antiretrovirals, Basic science and immunology.
ABT-378/r (lopinavir) now available on named patient basis in UK
15 May 2000. Related: Antiretrovirals.
Enteric coated ddI available on named patient basis in UK
15 May 2000. Related: Antiretrovirals.
Nelfinavir potency concerns
15 May 2000. Related: Antiretrovirals.